In the largest comparison of angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors to date, a study of nearly 2.3 million patients starting the drugs as monotherapy ...

In more than 3 million people worldwide treated for hypertension, ARBs were not only just as effective as ACE inhibitors at reducing the risk of major cardiovascular events, but also associated with a ...

Patients with heart failure who start taking sacubitril/valsartan (Entresto; Novartis) do not appear to have a greater risk of angioedema than do those who opt for an ACE inhibitor or ARB instead, an ...

Close-up of senior black woman sorting weekly medication. Member of a black middle class America family. Currently, ACE inhibitors and ARBs are both recommended as first-line therapies for the ...